Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab + Azacitidine in Japanese Patients with AML/MDS
NCT04241549Phase 1Completed
- Sponsor
- OncoVerity
- Start
- Mar 2020
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cusatuzumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by OncoVerity. Primary endpoints: Adverse Events and Serious Adverse Events up to 3 years, Dose-Limiting Toxicity up to 42 days and 1 more. Started Mar 2020; status: completed.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04241549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241549.